XML 27 R17.htm IDEA: XBRL DOCUMENT
v3.22.1

Share-based Compensation | 9 Months Ended
--- | ---
Mar. 31, 2022
Share-based Compensation | Note 10. Share-based Compensation We use equity-based compensation programs to provide long-term performance incentives for our employees. These incentives consist primarily of s tock options and RSUs. In December 2008, we adopted the MEI Pharma, Inc. 2008 Stock Omnibus Equity Compensation Plan (“Omnibus Plan”), as amended and restated from time-to-time, under which 29,014,794 shares of common stock are authorized for issuance. The Omnibus Plan provides for the grant of options and/or other stock-based or stock-denominated awards to our non-employee directors, officers, employees and advisors. As of March 31, 2022, there were 8,347,062 shares available for future grant under the Omnibus Plan. In May 2021, we adopted the 2021 Inducement Plan ("Inducement Plan"), under which 2,500,000 shares of common stock are authorized for issuance. The Inducement Plan is intended to assist us in attracting and retaining selected individuals to serve as employees who are expected to contribute to our success, by providing an inducement for such individuals to enter into employment with us, and to achieve long-ter m objectives that will benefit stockholders of the Company. As of March 31, 2022, there were 243,000 shares available for future grant under the Inducement Plan. Total share-based compensation expense for all stock awards consists of the following (in thousands):
|  | Three Months Ended March 31, |  |  | Nine Months Ended March 31, |
|  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Research and development |  | $ | 1,118 |  |  | $ | 1,207 |  |  | $ | 2,398 |  |  | $ | 3,496 |
General and administrative |  |  | 1,719 |  |  |  | 1,438 |  |  |  | 5,302 |  |  |  | 4,700 |
Total share-based compensation |  | $ | 2,837 |  |  | $ | 2,645 |  |  | $ | 7,700 |  |  | $ | 8,196 |
Stock Options Stock option activity for the nine months ended March 31, 2022 was as follows:
|  | Number of Options |  |  | Weighted- Average Exercise Price |  |  | Weighted-Average Remaining Contractual Term (in years) |  |  | Aggregate Intrinsic Value |
Outstanding at June 30, 2021 |  |  | 16,668,542 |  |  | $ | 3.01 |  |  |  |  |  |  |
Granted |  |  | 6,694,734 |  |  |  | 2.71 |  |  |  |  |  |  |
Exercised |  |  | (348,547 | ) |  |  | 1.64 |  |  |  |  |  |  |
Forfeited / Cancelled |  |  | (2,423,119 | ) |  |  | 3.15 |  |  |  |  |  |  |
Outstanding at March 31, 2022 |  |  | 20,591,610 |  |  |  | 2.91 |  |  |  | 7.7 |  |  | $ | 738 |
Vested and exercisable at March 31, 2022 |  |  | 10,115,129 |  |  |  | 2.93 |  |  |  | 6.4 |  |  | $ | — |
The fair value of each stock option granted during the nine months ended March 31, 2022 is estimated on the grant date under the fair value method using a Black-Scholes valuation model. Stock options granted to employees during the nine months ended March 31, 2022 vest 25% one year from the date of grant and ratably each month thereafter for a period of 36 months and expire ten years from the date of grant. Stock options granted to directors during the nine months ended March 31, 2022 vest ratably each month for a period of 12 months from the date of grant and expire ten years from the date of grant. The estimated fair values of the stock options, including the effect of estimated forfeitures, are expensed over the service period. The following weighted-average assumptions were used to determine the fair value of options granted during the period:
|  | Nine Months Ended March 31, |
|  | 2022 |  |  | 2021 |
Risk-free interest rate |  |  | 1.2 | % |  |  | 0.5 | %
Expected life (years) |  |  | 6.0 |  |  |  | 6.0 |
Expected volatility |  |  | 68.8 | % |  |  | 81.1 | %
Dividend yield |  |  | 0.0 | % |  |  | 0.0 | %
Weighted-average grant date fair value |  | $ | 1.65 |  |  | $ | 2.32 |
As of March 31, 2022, there was $9.5 million of unrecognized compensation expense related to the unvested portion of stock options. Such compensation expense is expected to be recognized over a weighted-average period of 1.7 years. Restricted Stock Units RSU activity for the nine months ended March 31, 2022 was as follows:
|  | Number of RSUs |  |  | Weighted-Average Grant Date Fair Value |
Non-vested at June 30, 2021 |  |  | 400,650 |  |  | $ | 3.49 |
Vested |  |  | (130,000 | ) |  | $ | 3.49 |
Forfeited / Cancelled |  |  | (46,250 | ) |  | $ | 3.49 |
Non-vested at March 31, 2022 |  |  | 224,400 |  |  | $ | 3.49 |
Each RSU represents the contingent right to receive one share of our common stock. Under the terms of the Omnibus Plan, each of the RSUs is calculated as 1.25 shares of common stock for purposes of determining the number of shares available for future grant. During the nine months ended March 31, 2022, 130,000 RSUs vested. We issued 63,855 shares of common stock to RSU holders; 66,145 shares were surrendered to us by RSU holders as payment for the employee portion of the required withholding of associated payroll taxes. As of March 31, 2022, unrecognized compensation expense related to the unvested portion of our RSUs was approximately $0.1 million and is expected to be recognized over approximately three months.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration